Try our beta test site

Reconstitution of HIV-specific Immunity Against HIV

This study is currently recruiting participants. (see Contacts and Locations)
Verified September 2015 by Guangzhou 8th People's Hospital
Sponsor:
Collaborator:
Sun Yat-sen University
Information provided by (Responsible Party):
Linghua LI, Guangzhou 8th People's Hospital
ClinicalTrials.gov Identifier:
NCT02563509
First received: September 13, 2015
Last updated: September 28, 2015
Last verified: September 2015
  Purpose
Research Goal: To reconstitute the anti-HIV specific immunity system of the AIDS patients, so the viruses could not massively replicate when HAART was discontinued, then make HIV functional cure possible.

Condition Intervention Phase
HIV
Other: HIV-specific CD8 cells
Phase 1
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single Blind (Subject)
Primary Purpose: Treatment
Official Title: Reconstitution of HIV-specific Immunity Against HIV

Resource links provided by NLM:


Further study details as provided by Guangzhou 8th People's Hospital:

Primary Outcome Measures:
  • The number and function of HIV-specific CD8 cells in patients with HIV [ Time Frame: 6 Months ]
    The change of differentiation, proliferation, apoptosis, phenotype, etal.


Secondary Outcome Measures:
  • All adverse events [ Time Frame: 6 Months ]
    Chills, Fever, Headache, Nausea, Vomiting, Cough, Skin rashes, Anaphylactic shock, Etal.


Estimated Enrollment: 40
Study Start Date: January 2013
Estimated Study Completion Date: December 2016
Estimated Primary Completion Date: January 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: HIV-specific CD8 cells
Transfusing HIV-specific CD8 cells 50-100mlonce a week for four times.
Other: HIV-specific CD8 cells
Only receive HAART
No Intervention: Regualar therapy
Only receiving Highly active anti-retroviral therapy(HAART).

Detailed Description:
The research aims at establishing a new treatment strategies of HIV. It will significantly improve the clinical therapy effects and effectively reduce the morbidity and mortality by reconstituting the immune systems of HIV infected patients and combining multiple therapy strategies. Therefore, the research could develop an cloning amplification system of immunocytes in vitro, and improve the antiviral immune system severely damaged before by transfusing the clone cells modified by specific HIV antigen. So HIV infected patients could discontinue the traditional anti-viral drug, but not develop opportunistic infections,which could obviously increase the life qualities of these patients.
  Eligibility

Ages Eligible for Study:   16 Years to 60 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. HIV infection confirmed
  2. Receiving HAART more than 6 months
  3. HIV viral-load < 50 copies/ml
  4. Without serious damage of liver and kidney
  5. The subject volunteered to the research and sign the informed consent

Exclusion Criteria:

  1. With serious opportunistic infections
  2. With serious chronic disease such like diabetes, the mental illness,et al
  3. History of suffering from pancreatitis during HAART.
  4. Pregnant and breast-fed.
  5. With poor adherence
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT02563509

Contacts
Contact: LingHua LI, doctor 13725297174 llheliza@126.com

Locations
China, Guangdong
Guangzhou 8th People's Hospital Recruiting
Guangzhou, Guangdong, China, 510060
Contact: Linghua LI, doctor    13725297174    llheliza@126.com   
Sponsors and Collaborators
Guangzhou 8th People's Hospital
Sun Yat-sen University
Investigators
Principal Investigator: Hui Zhang, doctor Sun Yat-sen University
  More Information

Publications:

Responsible Party: Linghua LI, Chief physician, Guangzhou 8th People's Hospital
ClinicalTrials.gov Identifier: NCT02563509     History of Changes
Other Study ID Numbers: 2013ZX10001004
Study First Received: September 13, 2015
Last Updated: September 28, 2015

Keywords provided by Guangzhou 8th People's Hospital:
HIV
cellular immunity therapy
functional cure

ClinicalTrials.gov processed this record on March 30, 2017